Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. Issue 4 (April 2022)
- Record Type:
- Journal Article
- Title:
- Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. Issue 4 (April 2022)
- Main Title:
- Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression
- Authors:
- Townsend, Liam
Dyer, Adam H.
Naughton, Aifric
Imangaliyev, Sultan
Dunne, Jean
Kiersey, Rachel
Holden, Dean
Mooney, Aoife
Leavy, Deirdre
Ridge, Katie
Sugrue, Jamie
Aldoseri, Mubarak
Kelliher, Jo Hannah
Hennessy, Martina
Byrne, Declan
Browne, Paul
Bacon, Christopher L.
Doyle, Catriona
O'Riordan, Ruth
McLaughlin, Anne-Marie
Bannan, Ciaran
Martin-Loeches, Ignacio
White, Arthur
McLoughlin, Rachel M.
Bergin, Colm
Bourke, Nollaig M.
O'Farrelly, Cliona
Conlon, Niall
Cheallaigh, Clíona Ní - Abstract:
- Abstract: SARS-CoV-2 infection causes a wide spectrum of disease severity. Identifying the immunological characteristics of severe disease and the risk factors for their development are important in the management of COVID-19. This study aimed to identify and rank clinical and immunological features associated with progression to severe COVID-19 in order to investigate an immunological signature of severe disease. One hundred and eight patients with positive SARS-CoV-2 PCR were recruited. Routine clinical and laboratory markers were measured, as well as myeloid and lymphoid whole-blood immunophenotyping and measurement of the pro-inflammatory cytokines IL-6 and soluble CD25. All analysis was carried out in a routine hospital diagnostic laboratory. Univariate analysis demonstrated that severe disease was most strongly associated with elevated CRP and IL-6, loss of DLA-DR expression on monocytes and CD10 expression on neutrophils. Unbiased machine learning demonstrated that these four features were strongly associated with severe disease, with an average prediction score for severe disease of 0.925. These results demonstrate that these four markers could be used to identify patients developing severe COVID-19 and allow timely delivery of therapeutics. Graphical abstract: Image 1 Highlights: Severe COVID-19 is characterised by a combination of emergency myelopoiesis and inflammation. These changes can be rapidly identified in a diagnostic laboratory, facilitating intervention.Abstract: SARS-CoV-2 infection causes a wide spectrum of disease severity. Identifying the immunological characteristics of severe disease and the risk factors for their development are important in the management of COVID-19. This study aimed to identify and rank clinical and immunological features associated with progression to severe COVID-19 in order to investigate an immunological signature of severe disease. One hundred and eight patients with positive SARS-CoV-2 PCR were recruited. Routine clinical and laboratory markers were measured, as well as myeloid and lymphoid whole-blood immunophenotyping and measurement of the pro-inflammatory cytokines IL-6 and soluble CD25. All analysis was carried out in a routine hospital diagnostic laboratory. Univariate analysis demonstrated that severe disease was most strongly associated with elevated CRP and IL-6, loss of DLA-DR expression on monocytes and CD10 expression on neutrophils. Unbiased machine learning demonstrated that these four features were strongly associated with severe disease, with an average prediction score for severe disease of 0.925. These results demonstrate that these four markers could be used to identify patients developing severe COVID-19 and allow timely delivery of therapeutics. Graphical abstract: Image 1 Highlights: Severe COVID-19 is characterised by a combination of emergency myelopoiesis and inflammation. These changes can be rapidly identified in a diagnostic laboratory, facilitating intervention. This disease signature was derived from a cohort of patients with a wide range of ages, frailty and COVID-19 severity. Abstract : COVID-19; Immune phenotype; Neutrophil maturity; Machine learning; Biomarkers. … (more)
- Is Part Of:
- Heliyon. Volume 8:Issue 4(2022)
- Journal:
- Heliyon
- Issue:
- Volume 8:Issue 4(2022)
- Issue Display:
- Volume 8, Issue 4 (2022)
- Year:
- 2022
- Volume:
- 8
- Issue:
- 4
- Issue Sort Value:
- 2022-0008-0004-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-04
- Subjects:
- COVID-19 -- Immune phenotype -- Neutrophil maturity -- Machine learning -- Biomarkers
Research -- Periodicals
Medical sciences -- Periodicals
Natural history -- Periodicals
Social sciences -- Periodicals
Earth sciences -- Periodicals
Physical sciences -- Periodicals
507.2 - Journal URLs:
- http://www.sciencedirect.com/science/journal/24058440/ ↗
http://www.sciencedirect.com/ ↗ - DOI:
- 10.1016/j.heliyon.2022.e09230 ↗
- Languages:
- English
- ISSNs:
- 2405-8440
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21393.xml